Annovis Q2 Loss Widens to $0.40/Share; Cash at $18.7M, Warrant Liability Jumps to $19.9M
ANVS sits 20% above its 52-week low of $1.541.
Summary
Annovis Bio reported a wider Q2 net loss of $0.40 per share, with cash at $18.7 million and a $19.9 million warrant liability. The pivotal Phase 3 Alzheimer's trial is fully enrolled with 850 patients, and topline data is expected in Q1 2027.
Key Events · Earnings and Guidance · ANVS
-
Q2 Net Loss Widens
Net loss per share increased to $0.40 from $0.32 a year ago, driven by R&D expenses more than doubling to $12.0 million.
-
Cash Position Declines
Cash and cash equivalents totaled $18.7 million as of June 30, 2026, down from $19.5 million at year-end 2025.
-
Warrant Liability Surges
Warrant liability jumped to $19.9 million from $0.6 million at year-end, reflecting fair-value remeasurement of warrants issued in the May 2026 offering.
-
Phase 3 AD Trial Fully Enrolled
Pivotal Phase 3 Alzheimer's trial enrolled 850 patients, exceeding the original target of 760; topline data expected in Q1 2027.
Analysis · ANVS · Life Sciences
Annovis Bio reported a wider Q2 net loss of $0.40 per share, up from $0.32 a year ago, driven by a more than doubling of R&D expenses to $12.0 million. Cash and cash equivalents fell to $18.7 million as of June 30, 2026, while the warrant liability surged to $19.9 million from $0.6 million at year-end, reflecting the fair-value remeasurement of warrants issued in the May 2026 offering. The company reiterated its going concern warning and highlighted full enrollment of its pivotal Phase 3 Alzheimer's trial with 850 patients, exceeding the original target of 760. Topline data from the 6-month analysis is expected in Q1 2027, with the disease-modifying readout a year later. The balance sheet shows negative stockholders' equity of $4.3 million, underscoring the company's reliance on dilutive capital raises to fund operations.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $1.85 on NYSE in the Life Sciences sector, with a market capitalization of approximately $78.7M. The 52-week trading range was $1.54 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.